REPLY
22.3.2024 09:31:34 CET | Business Wire | Press release
LEApedia, an AI-based assistant for warehouse management systems (WMS), won the coveted "Best Product LogiMAT 2024" award in the "Software, Communication & IT" category at the opening ceremony of LogiMAT 2024. The application is seamlessly integrated into the LEA Reply™ cloud-native SaaS WMS solution, offered by Logistics Reply, the Reply Group specialists in delivering innovative software solutions for the digital supply chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322257679/en/
LEApedia revolutionizes the way you interact with your warehouse management system (WMS) and other supply chain tools, with the integration of a powerful multi-agent AI engine to enhance efficiency, streamline operations, and unlock new insights. LEApedia facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. (Graphic: Business Wire)
The award, which is considered one of the most coveted in the intralogistics industry, is presented at the International Trade Fair for Intralogistics and recognizes outstanding achievements in the logistics sector that significantly optimise internal logistics processes, reduce costs and increase productivity.
LEApedia, which helps to improve logistics management processes, stands at the forefront of warehouse management system (WMS) innovation powered by an advanced multi-agent AI engine. This engine facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. At its core, LEApedia leverages a state-of-the-art Language Model, designed to interpret and respond to natural language queries and commands. This capability ensures users can interact with the system efficiently, significantly improving usability and accessibility.
Furthermore, LEApedia's smart search functionality allows for quick and intuitive access to information, ranging from specific terms to complex process descriptions. This feature is instrumental in navigating the system, ensuring users can find the information they need with unprecedented ease and speed. LEApedia enhances the system's efficiency and user-friendliness, setting a new standard for WMS solutions.
LEApedia is tailored to the specific needs and software environment of each customer. This makes it suitable for small businesses as well as medium-sized handling centres and large players. The module can be integrated into the system in a very short timeframe without slowing down or interrupting operations. It can also be updated during regular business without disruptions.
"The LogiMAT 2024 award is further proof of the tremendous performance of our WMS solution, which we are continuously evolving to take time-to-value and quality to new levels and support our customers in every step of their digital transformation journey. Technologies such as generative AI and machine learning help improve supply chain visibility and enable proactive decision making. The LEApedia AI-powered assistant offers users new opportunities to efficiently scale their WMS during ongoing warehouse operations and compete in the dynamic logistics industry," concluded Enrico Nebuloni, Executive Partner at Reply.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Logistics Reply
Logistics Reply provides cutting-edge software solutions that help companies achieve an efficient and more connected digital supply chain where different systems, partners, humans and machines seamlessly interact embracing the use of next-generation technologies such as AI, robotics, wearables and IoT. Logistics Reply accompanies its customers in this transformation journey ensuring rapid time-to-value and long-term quality results thanks to over 20 years of experience and deep knowledge of technologies and supply chain processes. www.lea.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322257679/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom